ANI Pharma (ANIP) Tops Q3 EPS by 12c, Reaffirms Guidance

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.29, $0.12 better than the analyst estimate of $1.17. Revenue for the quarter came in at $50.7 million versus the consensus estimate of $50.96 million.

GUIDANCE:

ANI Pharma sees FY2018 EPS of $4.80-$5.27, versus the consensus of $4.91. ANI Pharma sees FY2018 revenue of $195-205 million, versus the consensus of $200.04 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Hongli Group receives Nasdaq minimum bid price deficiency notice
• Northern Technologies (NTIC) Misses Q3 EPS by 12c